REGENXBIO, Inc. Ownership
$7.43
0.13%
Nasdaq, Oct 02, 04:26 pm EDT.
Closed.
Index
Industry
REGENXBIO, Inc. Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Redmile Group, LLC
|
4.369m | 8.07% | — | Jun 30 2026 |
| 2 |
BlackRock Institutional Trust Company, N.A.
|
4.361m | 8.05% | +401.746k | Jun 30 2026 |
| 3 |
State Street Investment Management (US)
|
2.971m | 5.49% | +239.688k | Jun 30 2026 |
| 4 |
Fox (Allan Mark)
|
2.911m | 5.38% | +9.807k | May 29 2026 |
| 5 |
Vanguard Capital Management, LLC
|
2.108m | 3.89% | +100.411k | Jun 30 2026 |
|
1
Redmile Group, LLC
|
8.07%
4.369m
|
|
2
BlackRock Institutional Trust Company, N.A.
|
8.05%
4.361m
|
|
3
State Street Investment Management (US)
|
5.49%
2.971m
|
|
4
Fox (Allan Mark)
|
5.38%
2.911m
|
|
5
Vanguard Capital Management, LLC
|
3.89%
2.108m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 30.87% of REGENXBIO, Inc., with Redmile Group, LLC the biggest at 8.07%, followed by BlackRock Institutional Trust Company, N.A. (8.05%) and State Street Investment Management (US) (5.49%). |
Recent REGENXBIO, Inc. Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 03 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 30 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 26 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 21 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 15 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 08 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 03 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 30 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 26 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 21 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 15 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 08 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
REGENXBIO, Inc. Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in REGENXBIO, Inc. has held steady at around 12.7% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
